Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Exelixis first-quarter revenues increase to $42.2 million

Exelixis first-quarter revenues increase to $42.2 million

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Novel combined immunotherapy promising for treatment of malignant brain tumors

Novel combined immunotherapy promising for treatment of malignant brain tumors

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN reports 20% revenue growth in first quarter 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.